Navigation Links
Novel compound halts tumor spread, improves brain cancer treatment in animal studies
Date:4/3/2012

Jennifer Munson, a former Fulbright Scholar who was a bioengineering graduate student in the Georgia Tech School of Chemical & Biomolecular Engineering when the research was conducted.

Arbiser designed the novel imipramine blue compound, which is an organic triphenylmethane dye. After in vitro experiments showed that imipramine blue effectively inhibited movement of several cancer cell lines, the researchers tested the compound in an animal model of aggressive cancer that exhibited attributes similar to a human brain tumor called glioblastoma.

"There were many reasons why we chose to use the RT2 astrocytoma rat model for these experiments," said Brat. "The tumor exhibited properties of aggressive growth, invasiveness, angiogenesis and necrosis that are similar to human glioblastoma; the model utilized an intact immune system, which is seen in the human disease; and the model enabled increased visualization by MRI because it was a rat model, rather than a mouse."

Because imipramine blue is hydrophobic and doxorubicin is cytotoxic, the researchers encapsulated each compound in an artificially-prepared vesicle called a liposome so that the drugs would reach the brain. The liposomal drug delivery vehicle also ensured that the drugs would not be released into tissue until they passed through leaky blood vessel walls, which are only present where a tumor is growing.

Animals received one of the following four treatments: liposomes filled with saline, liposomes filled with imipramine blue, liposomes filled with doxorubicin chemotherapy, or liposomes filled with imipramine blue followed by liposomes filled with doxorubicin chemotherapy.

All of the animals that received the sequential treatment of imipramine blue followed by doxorubicin chemotherapy survived for 200 days -- more than 6 months -- with no observable tumor mass. Of the animals treated with doxorubicin chemotherapy alone, 33 percent were alive after 200 days with a
'/>"/>

Contact: Abby Robinson
abby@innovate.gatech.edu
404-385-3364
Georgia Institute of Technology Research News
Source:Eurekalert  

Page: 1 2 3 4

Related biology technology :

1. John Grisham Joins Focused Ultrasound Surgery Foundation Board, Citing Novel Technologys Potential to Help Millions of Patients
2. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
3. UC Riverside researcher develops novel method to grow human embryonic stem cells
4. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
5. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
6. Spherics, Inc. Announces Sale of Novel Proprietary Bioadhesive Polymers and Oral Drug Delivery System
7. Arisyn Therapeutics Inc. Acquires Highly Novel Portfolio of Therapeutic Small Molecules for Infectious Disease and Cancer
8. Morria Biopharmaceuticals Plc Announces Results From its Pre-Clinical Screening of Novel Anti-Inflammatory Compounds
9. Novel Mass Spectrometry-based Assay Reveals Degradation and Low Levels of Bioactive B-type Natriuretic Peptide (BNP) in Patients with Heart Failure
10. Sensorin Raises Equity Financing to Launch Novel Industrial Sensing Venture
11. Trius Awarded $28 Million Contract to Develop Novel Antibiotics
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Novel compound halts tumor spread, improves brain cancer treatment in animal studies
(Date:12/24/2014)... 2014 Earlier this year in a ... director of the Adult Stem Cell Technology Center, LLC ... and under appreciated unique property of adult tissue stem ... Cells: Misunderstood in the Past, Important for the Future,” ... He gave the address at the 4th World ...
(Date:12/24/2014)... Island, New York (PRWEB) December 23, 2014 ... and the Long Island Affiliate of ITRA Global, the national ... slow but steady recovery. This is evidenced by the ... the strong stock market. Low energy costs have held ... The only negative is the housing market remaining soft. ...
(Date:12/24/2014)... The report expects global cell isolation and ... also provides a carefully analyzed data about the vital ... market. , Full Copy of Report @ http://bit.ly/1yUxy0T ... for cell expansion will keep witnessing growth at an ... to be driven by rapid technological advancements, government funding ...
(Date:12/24/2014)... AUSTIN, Texas , Dec. 23, 2014 /PRNewswire/ ... solutions company focused on gynecologic disease, announced today ... W. Schuler , Birchview Fund LLC and several ... million of unregistered shares of Vermillion,s common stock ... common stock in a private placement.  ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5
... LA JOLLA, Calif., Jan. 17, 2012  Synthetic Genomics Inc. ... solutions to solve a wide range of global challenges, ... Vice President for Nutritional Products. Stagnitti is a proven ... translating these into high value food and nutritional products ...
... Jan. 17, 2012 Reliv International, Inc. (NASDAQ: ... of LunaRich™, an exclusive soy powder developed at the Missouri ... of its nutritional supplements and will reveal that product at ... "Biotechnology is vital to Missouri,s economic future," said ...
... Inc. (NASDAQ: VVUS ) today announced that ... The Journal of Sexual Medicine (JSM), a peer-reviewed ... randomized, placebo-controlled, phase 3 study evaluating the safety and ... by the Food and Drug Administration (FDA) for the ...
Cached Biology Technology:Synthetic Genomics Inc. Hires Industry Leader George E. Stagnitti to Head Food and Nutritional Products Development Program 2Reliv and Soy Labs Launch LunaRich, a Healthier Soy 2Reliv and Soy Labs Launch LunaRich, a Healthier Soy 3Reliv and Soy Labs Launch LunaRich, a Healthier Soy 4REVIVE Trial Results for Avanafil Published in JSM Demonstrate Significant Improvement in Erectile Function 2REVIVE Trial Results for Avanafil Published in JSM Demonstrate Significant Improvement in Erectile Function 3REVIVE Trial Results for Avanafil Published in JSM Demonstrate Significant Improvement in Erectile Function 4REVIVE Trial Results for Avanafil Published in JSM Demonstrate Significant Improvement in Erectile Function 5REVIVE Trial Results for Avanafil Published in JSM Demonstrate Significant Improvement in Erectile Function 6
(Date:12/17/2014)... -- Automation is fundamentally transforming the travel experience and ... borders. Over the past decade, ePassports, biometric readers, ... to self process through border control via eGates ... increasing number of airports, seaports, and land borders ... Maxine Most , Principal at Acuity Market ...
(Date:12/11/2014)... 2014  Data Sciences International (DSI), the global ... new series of digital telemetry implants to meet ... series, part of the PhysioTel™ Digital platform, was ... physiologic data when incorporating functional endpoints into repeat-dose ... toxicology studies has evolved from short ECG strips ...
(Date:12/10/2014)... Dec. 08, 2014 Research and Markets ... of the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration ... as rural banking and upgradation of the driver,s ... in the market. Besides the aforementioned projects, biometrics ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... aimed at preventing cervical cancer is nearly 100 percent effective ... for most cases of cervical cancer. Results of a nationwide ... 9 issue of the New England Journal of Medicine. , ... deaths in women worldwide, resulting in nearly half a million ...
... helping to build a compelling case for oncolytic ... many cancers. , Reovirus, a non-pathogenic ... has shown powerful anti-cancer activity against cultured tumor ... trials. Oncolytics' proprietary reovirus formulation, Reolysin®, is active ...
... Universitat Autònoma de Barcelona, in cooperation with the animal ... model which faithfully reproduces the characteristics of dog’s skin ... various lines of research related to skin biology and ... The basic structure of skin consists of an external ...
Cached Biology News:Study shows continued success for new HPV vaccine against virus responsible for cervical cancer 2Dealing deadly cancers a knockout punch 2Dealing deadly cancers a knockout punch 3
Human M-CSF...
Human Serpin B5/Maspin Affinity Purified Polyclonal Ab...
... and S.J. Allen (1995) This ... world authorities on current issues relating to ... Several major advances have been made recently ... disease. Topics include molecular neuropathology through clinical ...
Normal human serum, single donor...
Biology Products: